norovirus and glp 1 Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? Could a Stomach Virus Mimic

ArticlePubMed 8

Sugio, S., Kashima, A., Mochizuki, S., Noda, M

34 The FOCUS Trial should shed light on how many patients treated with GLP-1/GIP agonists experience significant worsening of their DR and macular edema

The compound's effects on insulin sensitivity and glucose metabolism require regular laboratory assessment, but many providers offer inadequate monitoring protocols

2015;308(5):E41425

The KLOW stack peptide combines GHK-Cu (glycyl-L-histidyl-L-lysine copper complex, 50mg), BPC-157 (body protection compound 15-mer, 10mg), TB-500 (synthetic Thymosin Beta-4 analogue, 10mg), and KPV (Lys-Pro-Val C-terminal alpha-MSH tripeptide, 10mg) in a single co-lyophilized 80mg vial